Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D Investments

Considering the gross negative impact of the PLS on R&D investments of pharmaceutical firms and the heterogeneous response of these firms by the R&D activities, governmental efforts of cost-containment may need to consider the spillover impact of the PLS on pharmaceutical innovation.